SUCCINCT: An open-label, single-arm, non-randomised, phase 2 trial of gemcitabine and cisplatin chemotherapy in combination with Sunitinib as first-line treatment for patients with advanced urothelial carcinoma
Gemcitabine and cisplatin chemotherapy (GC regimen) represents a standard treatment for advanced urothelial carcinoma. We performed an open-label, single-arm, non-randomised, phase 2 trial evaluating the addition of sunitinib to standard GC chemotherapy (SGC regimen). Overall, 63 treatment-naïve pa...
Main Authors: | Geldart, Thomas (Author), Chester, John (Author), Casbard, Angela (Author), Crabb, Simon (Author), Elliott, Tony (Author), Protheroe, Andrew (Author), Huddart, Robert A. (Author), Mead, Graham (Author), Barber, Jim (Author), Jones, Robert J. (Author), Smith, Joanna (Author), Cowles, Robert (Author), Evans, Jessica (Author), Griffiths, Gareth (Author) |
---|---|
Format: | Article |
Language: | English |
Published: |
2015-04.
|
Subjects: | |
Online Access: | Get fulltext |
Similar Items
-
Impact of relative dose intensity in gemcitabine–cisplatin chemotherapy for metastatic urothelial carcinoma
by: Naoki Kohei, et al.
Published: (2018-06-01) -
Succinct Indexes
by: He, Meng
Published: (2008) -
Succinct Indexes
by: He, Meng
Published: (2008) -
Combination of gemcitabine and carboplatin in urothelial cancer patients unfit for cisplatin due to impaired renal or cardiac function
by: Avishay Sella, et al.
Published: (2012-02-01) -
Pathologic Response Rates of Gemcitabine/Cisplatin versus Methotrexate/Vinblastine/Adriamycin/Cisplatin Neoadjuvant Chemotherapy for Muscle Invasive Urothelial Bladder Cancer
by: Franklin C. Lee, et al.
Published: (2013-01-01)